Case study supports efficacy of biliary diversion surgery for PFIC4
Biliary diversion surgery — which can be used in patients with bile duct problems — successfully reduced markers of liver damage, lessened itching, and improved…
News
Lanifibranor may be reason for liver gains seen in Phase 3 MASH trial
Signs of improved liver health are evident in biomarker and liver scarring assessments of people with metabolic-associated steatohepatitis or MASH — a severe form of…
Blood marker may predict biliary atresia liver transplant need: Study
A non-invasive liver function score called the aspartate aminotransferase to platelet ratio index (APRI) may help accurately predict whether adult biliary atresia (BA) patients…
Researcher secures NIH funding to study hepatitis E virus
A researcher at the Virginia-Maryland College of Veterinary Medicine received a $2 million award from the National Institutes of Health (NIH) to continue research into…
Iqirvo wins EU’s conditional OK to treat primary biliary cholangitis
Iqirvo (elafibranor) has been conditionally approved in the European Union to treat adults with primary biliary cholangitis (PBC), either in combination with the…
Abnormal blood lipid levels linked with ICP, pregnancy complications
Abnormal levels of certain fatty molecules, or lipids, in the blood appear to increase the risk of intrahepatic cholestasis of pregnancy (ICP) and its…
Potential THR-beta agonist may more safely, effectively treat MASH
Once daily treatment with oral ALG-055009 safely lowered levels of liver fat in people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty…
New NOTCH2 gene mutations identified as likely Alagille cause
Researchers in Italy have identified 10 new mutations in the NOTCH2 gene, which has been linked to Alagille syndrome, in nine children and one…
Key protein flattens with one-time chronic hepatitis B treatment
Chroma Medicine’s investigational one-time treatment CRMA-1001 for chronic hepatitis B brought levels of a key hepatitis B virus (HBV) protein to nearly 0 in…
FDA committee votes 10-1 against Ocaliva’s full approval for PBC
A U.S. Food and Drug Administration (FDA) advisory committee voted 10-1 that Ocaliva (obeticholic acid) doesn’t have a benefit-risk profile that would support its…
